Biocon Limited has officially launched Bosaya™ and Aukelso™, its denosumab biosimilars, in the U.S. market. Both products received interchangeable designation from the FDA in September 2025, allowing for pharmacy-level substitution. Targeting patients with osteoporosis and bone metastases, these therapies address a significant $5 billion market. This launch reinforces Biocon’s oncology and immunology leadership and its commitment to providing high-quality, affordable treatment options to patients and health systems nationwide.
Expanding Treatment Access
Biocon Limited has officially initiated the U.S. commercial rollout of Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab-kyqq). As biosimilars to Prolia® and Xgeva®, respectively, these medications are now available nationwide through specialty pharmacies and healthcare providers. The launch follows a critical regulatory milestone in September 2025, when the products were granted interchangeable status, ensuring seamless transition and accessibility for patients.
Strategic Market Impact
The denosumab market in the U.S. represents approximately $5 billion in annual sales, highlighting a robust demand for cost-effective alternatives. These therapies are indicated for millions of adults suffering from osteoporosis, as well as over 330,000 patients annually who face bone complications from advanced cancer. By expanding its biosimilars portfolio, Biocon continues to leverage its research and development platform to enhance patient access to complex biologic treatments.
Product Specifications and Clinical Utility
Both products are designed for precision care in their respective clinical applications. Bosaya™ is available as a 60 mg/mL injection for subcutaneous use in a prefilled syringe, primarily serving osteoporosis patients. Aukelso™ is supplied as a 120 mg/1.7 mL injection in a single-dose vial for oncology-related indications, including bone metastases and giant cell tumor of bone. These offerings aim to mitigate the healthcare burden associated with skeletal conditions while maintaining the rigorous quality standards expected in biological medicine.
Source: BSE
